Dr Mafalda Oliveira speaks to ecancer about the primary results of the SOLTI VALENTINE trial.

This is a study on HER3 DXT and antibody drug conjugates for high-risk HR positive HER2 negative early breast cancer.

It evaluates anti-HER3 agents across three treatment arms, focusing on pathologic complete response rates.

Results show HER3 DXT's efficacy is comparable to multi-agent chemotherapy, with fewer severe adverse events.

Translational research indicates positive anti-proliferative responses, suggesting HER3 DXT as a promising option for high-risk patients.